Harbor Investment Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

Harbor Investment Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,685	Closed	-$118K	–	1146
2024 Q3	$118K	Hold	1,685	–	–	0.01%	423
2024 Q2	$139K	Hold	1,685	–	–	0.01%	386
2024 Q1	$147K	Hold	1,685	–	–	0.02%	386
2023 Q4	$162K	Hold	1,685	–	–	0.02%	356
2023 Q3	$149K	Hold	1,685	–	–	0.02%	345
2023 Q2	$146K	Hold	1,685	–	–	0.02%	412
2023 Q1	$164K	Hold	1,685	–	–	0.02%	389
2022 Q4	$174K	Hold	1,685	–	–	0.03%	362
2022 Q3	$143K	Hold	1,685	–	–	0.02%	391
2022 Q2	$140K	Sell	1,685 -91	-5%	-$7.25K	0.02%	410
2022 Q1	$137K	Sell	1,776 -636	-26%	-$53.2K	0.02%	458
2021 Q4	$213K	Hold	2,412	–	–	0.03%	364
2021 Q3	$186K	Hold	2,412	–	–	0.03%	381
2021 Q2	$201K	Hold	2,412	–	–	0.03%	369
2021 Q1	$182K	Buy	2,412 +1,685	+232%	+$138K	0.03%	356
2020 Q4	$64K	Sell	727 -1,274	-64%	-$101K	0.01%	569
2020 Q3	$152K	Buy	2,001 +406	+25%	+$41.1K	0.03%	321
2020 Q2	$197K	Buy	1,595 +1,354	+562%	+$135K	0.04%	263
2020 Q1	$20K	Buy	+241	New	+$20.8K	0.01%	575

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Harbor Investment Advisory's BMRN Position: Q4 2024 in Review

Harbor Investment Advisory sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 1,685 shares — an estimated $118K sold.

Harbor Investment Advisory first reported a position in BMRN in Q1 2020 and held it in 19 quarters. The position peaked at $213K in Q4 2021. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

Harbor Investment Advisory reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Harbor Investment Advisory sold 1,685 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $118K.
Harbor Investment Advisory first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 19 quarters.
Harbor Investment Advisory's BioMarin Pharmaceuticals position peaked at $213K in Q4 2021.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Harbor Investment Advisory's 13F filing for Q4 2024, filed 16 Jan 2025.